Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
Comparison of Clinical Efficacy of Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
1 other identifier
interventional
306
0 countries
N/A
Brief Summary
A large number of clinical studies have shown that oral administration, external application or enema of Chinese medicine can promote the recovery of gastrointestinal function and the absorption of pancreatic inflammation. The aims of the study is to explore the application of Dachaihu Decoction Compound (DDC)and Rhubarb Single Medicine (RSM) in the Treatment of Acute Pancreatitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2023
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 27, 2021
CompletedFirst Posted
Study publicly available on registry
August 4, 2021
CompletedStudy Start
First participant enrolled
September 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2029
March 24, 2022
July 1, 2021
5.4 years
July 27, 2021
March 22, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Significant and effective rate
Significant and effective rate after 7 days of treatment
7 days
Study Arms (3)
DDC(Dachaihu decoction compound) Group
EXPERIMENTALTreated with Dachaihu decoction compound and regular therapies
RSM(rhubarb single medicine) Group
ACTIVE COMPARATORTreated with rhubarb single medicine and regular therapies
N Group
OTHERTreated with regular therapies and without traditional Chinese medicine
Interventions
Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
Regular therapies, such as fluid therapy, for acute pancreatitis
Eligibility Criteria
You may qualify if:
- Age from 18 to 65 years old
- Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset
- Consent of the subjects, who sign the informed consent form
You may not qualify if:
- Women who are pregnant or breastfeeding
- Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc.
- Patients with a history of severe heart, liver, kidney and other important organ diseases
- Patients with mental illness and malignant tumors
- People who have allergies, or are allergic to a certain drug ingredient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2021
First Posted
August 4, 2021
Study Start
September 1, 2023
Primary Completion (Estimated)
January 31, 2029
Study Completion (Estimated)
July 31, 2029
Last Updated
March 24, 2022
Record last verified: 2021-07